Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Current Liabilities: 2023-2025

Historic Total Current Liabilities for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $6.4 million.

  • Contineum Therapeutics' Total Current Liabilities rose 9.56% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 9.56%. This contributed to the annual value of $10.0 million for FY2024, which is 81.87% up from last year.
  • According to the latest figures from Q3 2025, Contineum Therapeutics' Total Current Liabilities is $6.4 million, which was down 11.82% from $7.2 million recorded in Q2 2025.
  • Contineum Therapeutics' Total Current Liabilities' 5-year high stood at $10.0 million during Q4 2024, with a 5-year trough of $3.7 million in Q2 2024.
  • For the 3-year period, Contineum Therapeutics' Total Current Liabilities averaged around $6.7 million, with its median value being $6.3 million (2024).
  • Data for Contineum Therapeutics' Total Current Liabilities shows a peak YoY spiked of 92.94% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Contineum Therapeutics' Total Current Liabilities stood at $5.5 million in 2023, then spiked by 81.87% to $10.0 million in 2024, then rose by 9.56% to $6.4 million in 2025.
  • Its Total Current Liabilities was $6.4 million in Q3 2025, compared to $7.2 million in Q2 2025 and $8.9 million in Q1 2025.